Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update

Business Wire November 8, 2017

Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development

Business Wire September 19, 2017

Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”)

Business Wire September 11, 2017

2 Names Barclays Is Now Bearish On In Biotech

Benzinga.com  September 7, 2017

Zymeworks to Present at the European Society for Medical Oncology 2017 Congress and Hold Webcast to Review Clinical Results

Business Wire September 6, 2017

Zymeworks to Participate in Upcoming Healthcare and Biotech Conferences

Business Wire August 29, 2017

Zymeworks Reports Second Quarter 2017 Financial Results

Business Wire August 8, 2017

Zymeworks to Present at 37th Annual Canaccord Genuity Growth Conference

Business Wire August 4, 2017

Zymeworks Appoints Dr. Natalie Sacks to its Board of Directors

Business Wire August 3, 2017

Zymeworks to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017

Business Wire August 1, 2017

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration

Business Wire July 18, 2017

Drug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly

Business Wire June 12, 2017

Zymeworks Inc. Closes the Market

Canada NewsWire June 4, 2017

Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017)

Business Wire June 4, 2017

10 Biggest Mid-Day Losers For Thursday

Benzinga.com  June 1, 2017

Zymeworks Announces Closing of Partial Exercise of Over-Allotment Option for Its Initial Public Offering

Business Wire May 31, 2017

Zymeworks Announces Partial Exercise of Over-Allotment Option for its Initial Public Offering

Business Wire May 26, 2017

Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst

Benzinga.com  May 23, 2017

Zymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting

Business Wire May 17, 2017

Zymeworks Reports First Quarter 2017 Financial Results

Business Wire May 15, 2017